RAVI THAKUR

Dr. RAVI THAKUR

Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
+1
orcid
Assistant Professor at Christ University, exploring cancer m...

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2015 in Scientific Reports
Verified
Journal Article
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
RTRachana Trivedi
Rachana Trivedi
NRNamrata Rastogi
Namrata Rastogi
MSManisha Singh
Manisha Singh
DMDurga Prasad Mishra
Durga Prasad Mishra
Cancer stem cells (CSCs) are responsible for aggressive tumor growth, metastasis and therapy resistance. In this study, we evaluated the effects of Shikonin (Shk) on breast cancer and found its anti-CSC potential. Shk treatment decreased the expression of various epithelial to mesenchymal transition (EMT) and CSC associated markers. Kinase profiling array and western blot analysis indicated that Shk inhibits STAT3, FAK and Src activation. Inhibition of these signaling proteins using standard inhibitors revealed that STAT3 inhibition affected CSCs properties more significantly than FAK or Src inhibition. We observed a significant decrease in cell migration upon FAK and Src inhibition and decrease in invasion upon inhibition of STAT3, FAK and Src. Combined inhibition of STAT3 with Src or FAK reduced the mammosphere formation, migration and invasion more significantly than the individual inhibitions. These observations indicated that the anti-breast cancer properties of Shk are due to its potential to inhibit multiple signaling proteins. Shk also reduced the activation and expression of STAT3, FAK and Srcin vivoand reduced tumorigenicity, growth and metastasis of 4T1 cells. Collectively, this study underscores the translational relevance of using a single inhibitor (Shk) for compromising multiple tumor-associated signaling pathways to check cancer metastasis and stem cell load.

1 February 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
SSSudipta Senapati
Sudipta Senapati
RAVI THAKURRAVI THAKUR
RAVI THAKUR
SVShiv Prakash Verma
Shiv Prakash Verma
SDShivali Duggal
Shivali Duggal
DMDurga Prasad Mishra
Durga Prasad Mishra
PMPralay Maiti
Pralay Maiti

1 November 2021 in Gastroenterology
Verified
Journal Article
Open access
PDF file
THTuo Hu
Tuo Hu
SSSurendra K. Shukla
Surendra K. Shukla
EVEnza Vernucci
Enza Vernucci
CHChunbo He
Chunbo He
DWDezhen Wang
Dezhen Wang
PSPankaj Singh
Pankaj Singh
Background & Aims SIRT5 plays pleiotropic roles via post-translational modifications, serving as a tumor suppressor, or an oncogene, in different tumors. However, the role SIRT5 plays in the initiation and progression of pancreatic ductal adenocarcinoma (PDAC) remains unknown. Methods Published datasets and tissue arrays with SIRT5 staining were used to investigate the clinical relevance of SIRT5 in PDAC. Furthermore, to define the role of SIRT5 in the carcinogenesis of PDAC, we generated autochthonous mouse models with conditional Sirt5 knockout. Moreover, to examine the mechanistic role of SIRT5 in PDAC carcinogenesis, SIRT5 was knocked down in PDAC cell lines and organoids, followed by metabolomics and proteomics studies. A novel SIRT5 activator was used for therapeutic studies in organoids and patient-derived xenografts. Results SIRT5 expression negatively regulated tumor cell proliferation and correlated with a favorable prognosis in patients with PDAC. Genetic ablation of Sirt5 in PDAC mouse models promoted acinar-to-ductal metaplasia, precursor lesions, and pancreatic tumorigenesis, resulting in poor survival. Mechanistically, SIRT5 loss enhanced glutamine and glutathione metabolism via acetylation-mediated activation of GOT1. A selective SIRT5 activator, MC3138, phenocopied the effects of SIRT5 overexpression and exhibited antitumor effects on human PDAC cells. MC3138 also diminished nucleotide pools, sensitizing human PDAC cell lines, organoids, and patient-derived xenografts to gemcitabine. Conclusions Collectively, we identify SIRT5 as a key tumor suppressor in PDAC, whose loss promotes tumorigenesis through increased noncanonic use of glutamine via GOT1, and that SIRT5 activation is a novel therapeutic strategy to target PDAC.

1 March 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
DMDivya Murthy
Divya Murthy
KAKuldeep S. Attri
Kuldeep S. Attri
SSSurendra K. Shukla
Surendra K. Shukla
RAVI THAKURRAVI THAKUR
RAVI THAKUR
NCNina V. Chaika
Nina V. Chaika
PSPankaj Singh
Pankaj Singh
The ability of tumour cells to thrive in harsh microenvironments depends on the utilization of nutrients available in the milieu. Here we show that pancreatic cancer-associated fibroblasts (CAFs) regulate tumour cell metabolism through the secretion of acetate, which can be blocked by silencing ATP citrate lyase (ACLY) in CAFs. We further show that acetyl-CoA synthetase short-chain family member 2 (ACSS2) channels the exogenous acetate to regulate the dynamic cancer epigenome and transcriptome, thereby facilitating cancer cell survival in an acidic microenvironment. Comparative H3K27ac ChIP–seq and RNA–seq analyses revealed alterations in polyamine homeostasis through regulation of SAT1 gene expression and enrichment of the SP1-responsive signature. We identified acetate/ACSS2-mediated acetylation of SP1 at the lysine 19 residue that increased SP1 protein stability and transcriptional activity. Genetic or pharmacologic inhibition of the ACSS2–SP1–SAT1 axis diminished the tumour burden in mouse models. These results reveal that the metabolic flexibility imparted by the stroma-derived acetate enabled cancer cell survival under acidosis via the ACSS2–SP1–SAT1 axis.

1 April 2015 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SPSanjeev K. Pandey
Sanjeev K. Pandey
DPDinesh K. Patel
Dinesh K. Patel
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DMDurga P. Mishra
Durga P. Mishra
PMPralay Maiti
Pralay Maiti
CHChandana Haldar
Chandana Haldar

14 March 2013 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DMDurga Prasad Mishra
Durga Prasad Mishra
Beta‐catenin (β‐catenin) is a multifunction protein with a central role in physiological homeostasis. Its abnormal expression leads to various diseases including cancer. In normal physiology, β‐catenin either maintains integrity of epithelial tissues or controls transcription of various genes on extracellular instigations. In epithelial tissues, β‐catenin functions as a component of the cadherin protein complex and regulates epithelial cell growth and intracellular adhesion. In Wnt signalling, β‐catenin is a major transcriptional modulator and plays a crucial role in embryogenesis, stem cell renewal and organ regeneration. Aberrant expression of β‐catenin can induce malignant pathways in normal cells and its abnormal activity is also exploited by existing malignant programmes. It acts as an oncogene and modulates transcription of genes to drive cancer initiation, progression, survival and relapse. Abnormal expression and function of β‐catenin in cancer makes it a putative drug target. In the past decade, various attempts have been made to identify and characterize various pharmacological inhibitors of β‐catenin. Many of these inhibitors are currently being investigated for their anticancer activities in a variety of cancers. The first half of this review will focus on the role of β‐catenin in cancer initiation, maintenance, progression and relapse whereas the second half will briefly summarize the recent progress in development of agents for the pharmacological modulation of β‐catenin activity in cancer therapeutics.